English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The development of cervical cancer is highly dependent on the ability of cancer cells to form new capillaries and lymphatic vessels. Neo-adjuvant chemotherapy shrinks tumor size and reduces angiogenesis. Of the various growth factors that regulate angiogenesis, VEGF-C is the first-rank lymphangiogenic factor. VEGF-C can be measured by several methods. This study aimed to determine: (1) the effect of neo-adjuvant chemotherapy in reducing tissue VEGF-C expression and serum VEGF-C level; (2) the correlation between VEGF-C expression in tissueand serum VEGF-C in patients with bulky cervical cancer receiving paclitaxel – carboplatin neoadjuvan chemotherapy.  Subjects and Method: This was a quasi experiment conducted at the Obstetrics and Gynecology Department and the Pathology and Anatomy Department, Dr. Moewardi Hospital, Surakarta, Central Java, from May to September 2017. A sample of 30 patients with cervical cancer stage IB2 and IIA2 was selected for this study. The independent variable was paclitaxel – carboplatin neoadjuvan chemotherapy. The dependent variables were VEGF-C expression in tissue and VEGF-C serum. Tissue VEGF-C expression and serum VEGF-C level were measured before and after neo-adjuvant chemotherapy. The data were analyzed by Wilcoxon test and Spearman correlation.  Results: TissueVEGF-C expression before chemotherapy (mean= 6.17) was higher than after therapy (mean= 4.17), and it was statistically significant (p< 0.001). Serum VEGF-C level before chemotherapy (mean= 9574.60) was higher than after therapy (mean= 7827.63), and it was statistically significant (p= 0.006). Tissue VEGF-C expression was correlated with serum VEGF-C, but it was statistically non-significant (r= 0.15, p= 0.218).  Conclusion: Neo-adjuvant chemotherapy reduces both VEGF-C tissue expression and serum VEGF-C levels. There is a weak and insignificant correlation between tissue VEGF-C expression and serum VEGF-C levels in patients with cervical cancer given neo-adjuvant chemotherapy.  Keywords: VEGF-C, neo-adjuvant chemotherapy, cervical cancer

revitalizing family planning program and women’s empowerment for the improvement of population well-being and economic development

Correlation between Vegf-C Expression in Tissue and Serum Vegf-C in Patients with Bulky Cervical Cancer Receiving Paclitaxel – Carboplatin Neoadjuvan Chemotherapy